Verrica Pharmaceuticals Inc. 8-K Filing
Ticker: VRCA · Form: 8-K · Filed: Nov 24, 2025 · CIK: 1660334
| Field | Detail |
|---|---|
| Company | Verrica Pharmaceuticals Inc. (VRCA) |
| Form Type | 8-K |
| Filed Date | Nov 24, 2025 |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $4.24125, $4.24115 million, $0, $6 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Verrica Pharmaceuticals Inc. (ticker: VRCA) to the SEC on Nov 24, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (f the Company's common stock, par value $0.0001 (" Common Stock "), (ii) with respect t); $4.24125 (ck and accompanying Series C Warrant is $4.24125 per share (the " Purchase Price ") and); $4.24115 million (ceiving gross proceeds of approximately $4.24115 million from the Private Placement, before dedu); $0 (ants have a per share exercise price of $0.0001, subject to proportional adjustmen); $6 (and have a per share exercise price of $6.315, subject to proportional adjustment).
How long is this filing?
Verrica Pharmaceuticals Inc.'s 8-K filing is 6 pages with approximately 1,691 words. Estimated reading time is 7 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,691 words · 7 min read · ~6 pages · Grade level 12.4 · Accepted 2025-11-24 08:19:22
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 (" Common Stock "), (ii) with respect t
- $4.24125 — ck and accompanying Series C Warrant is $4.24125 per share (the " Purchase Price ") and
- $4.24115 million — ceiving gross proceeds of approximately $4.24115 million from the Private Placement, before dedu
- $0 — ants have a per share exercise price of $0.0001, subject to proportional adjustmen
- $6 — and have a per share exercise price of $6.315, subject to proportional adjustment
- $35.0 million — greement, the Company has agreed to use $35.0 million of the net proceeds of the Private Plac
- $125.0 m — an aggregate principal amount of up to $125.0 million, of which the Company had borrowe
- $50.0 million — lion, of which the Company had borrowed $50.0 million. The foregoing is only a summary of t
Filing Documents
- d692687d8k.htm (8-K) — 39KB
- d692687dex41.htm (EX-4.1) — 79KB
- d692687dex42.htm (EX-4.2) — 111KB
- d692687dex101.htm (EX-10.1) — 205KB
- d692687dex102.htm (EX-10.2) — 188KB
- d692687dex103.htm (EX-10.3) — 120KB
- d692687dex991.htm (EX-99.1) — 15KB
- g692687g1123111343871.jpg (GRAPHIC) — 3KB
- 0001193125-25-292155.txt ( ) — 1080KB
- vrca-20251123.xsd (EX-101.SCH) — 3KB
- vrca-20251123_lab.xml (EX-101.LAB) — 18KB
- vrca-20251123_pre.xml (EX-101.PRE) — 11KB
- d692687d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 4.1 Form of Pre-Funded Warrant. 4.2 Form of Series C Warrant. 10.1 Form of Securities Purchase Agreement with institutional investors, dated November 23, 2025 10.2 Form of Securities Purchase Agreement with other accredited investors, dated November 23, 2025 10.3 Form of Registration Rights Agreement, dated November 23, 2025, by and among Verrica Pharmaceuticals, Inc. and the Purchasers. 99.1 Press Release, dated November 24, 2025 104 Cover Page Interactive Data File (formatted as inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Verrica Pharmaceuticals Inc. Date: November 24, 2025 /s/ John J. Kirby John J. Kirby Interim Chief Financial Officer